- Be aware, the S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
- Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.
- This website is able to track outpatient clinic and locations that have Paxlovid available. Providers can visit: https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/
Paxlovid is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for the initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. Paxlovid is not a substitute for vaccination in individuals for whom COVID-19 vaccination and a booster dose are recommended. It is important that individuals who are eligible receive a COVID-19 vaccine and stay up to date on their vaccinations.
Fact sheets that provide important information about using Paxlovid in the treatment of COVID-19 as authorized is available for healthcare providers and to patients and caregivers. These fact sheets include dosing instructions, potential side effects, drug interactions and information about who is able to prescribe Paxlovid.
Generic Prescription Form for Paxlovid: here